United Therapeutics (NASDAQ:UTHR) CFO Sells $5,729,400.00 in Stock

Key Points

• United Therapeutics CFO James Edgemond sold 10,000 shares on May 26 at an average price of $572.94, totaling about $5.73 million. After the sale, he still held 18,876 shares, a 34.63% decrease in his position.
• Edgemond has been selling shares repeatedly over the past several weeks, including multiple 10,000-share sales in May and April, signaling a sustained reduction in his holdings.
• The stock slipped 1.3% to $570.75 amid the news. United Therapeutics also recently reported Q1 earnings that missed estimates, though analysts still rate the stock a “Moderate Buy” with a consensus price target of $619.42.

United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CFO James Edgemond sold 10,000 shares of the company's stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $572.94, for a total value of $5,729,400.00. Following the sale, the chief financial officer directly owned 18,876 shares in the company, valued at $10,814,815.44. This represents a 34.63% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

James Edgemond also recently made the following trade(s):

• On Thursday, May 21st, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $564.11, for a total value of $5,641,100.00.
• On Monday, May 18th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $567.31, for a total value of $5,673,100.00.
• On Thursday, May 14th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $574.47, for a total value of $5,744,700.00.
• On Monday, May 11th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $573.03, for a total value of $5,730,300.00.
• On Thursday, May 7th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $578.58, for a total value of $5,785,800.00.
• On Monday, May 4th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $576.93, for a total value of $5,769,300.00.
• On Thursday, April 30th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $572.61, for a total value of $5,726,100.00.
• On Monday, April 27th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $568.83, for a total value of $5,688,300.00.
• On Wednesday, April 22nd, James Edgemond sold 364 shares of United Therapeutics stock. The stock was sold at an average price of $575.85, for a total value of $209,609.40.
• On Thursday, April 23rd, James Edgemond sold 9,636 shares of United Therapeutics stock. The stock was sold at an average price of $572.21, for a total value of $5,513,815.56.

United Therapeutics Trading Down 1.3%

NASDAQ:UTHR traded down $7.68 during trading hours on Wednesday, hitting $570.75. The company's stock had a trading volume of 314,854 shares, compared to its average volume of 479,013. The stock has a market capitalization of $24.23 billion, a P/E ratio of 21.07, a price-to-earnings-growth ratio of 1.84 and a beta of 0.60. The stock has a fifty day moving average of $564.81 and a 200-day moving average of $513.93. United Therapeutics Corporation has a 52-week low of $272.12 and a 52-week high of $609.35.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing the consensus estimate of $7.00 by ($1.18). The business had revenue of $781.50 million during the quarter, compared to analysts' expectations of $797.40 million. United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The business's quarterly revenue was down 1.6% compared to the same quarter last year. During the same period last year, the company earned $6.63 EPS. On average, sell-side analysts forecast that United Therapeutics Corporation will post 27.07 earnings per share for the current year.

Hedge Funds Weigh In On United Therapeutics

Several hedge funds have recently made changes to their positions in UTHR. Torren Management LLC purchased a new position in shares of United Therapeutics during the fourth quarter worth about $26,000. Activest Wealth Management grew its holdings in shares of United Therapeutics by 1,400.0% during the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company's stock worth $29,000 after buying an additional 56 shares during the last quarter. WealthCollab LLC grew its holdings in shares of United Therapeutics by 55.9% during the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company's stock worth $30,000 after buying an additional 38 shares during the last quarter. Rakuten Securities Inc. grew its holdings in shares of United Therapeutics by 76.7% during the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company's stock worth $30,000 after buying an additional 46 shares during the last quarter. Finally, Entrust Financial LLC purchased a new position in shares of United Therapeutics during the fourth quarter worth about $31,000. Hedge funds and other institutional investors own 94.08% of the company's stock.

Analyst Ratings Changes

Several research firms recently commented on UTHR. Royal Bank Of Canada dropped their target price on United Therapeutics from $707.00 to $701.00 and set an "outperform" rating on the stock in a report on Thursday, May 7th. Cantor Fitzgerald increased their target price on United Therapeutics from $525.00 to $625.00 and gave the company an "overweight" rating in a report on Thursday, March 12th. Oppenheimer increased their target price on United Therapeutics from $575.00 to $600.00 and gave the company an "outperform" rating in a report on Thursday, February 26th. UBS Group increased their target price on United Therapeutics from $655.00 to $705.00 and gave the company a "buy" rating in a report on Thursday, March 5th. Finally, Jefferies Financial Group reissued a "buy" rating on shares of United Therapeutics in a report on Monday, March 2nd. Eleven research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $619.42.

United Therapeutics Company Profile

United Therapeutics Corporation NASDAQ: UTHR is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.